 Pacific Biosciences of California Inc NASDAQ: PACB, after the close of the market on Tuesday, reported Q2 sales of 30.6 million, beating the consensus of 29.9 million and up 79 YY. The Company placed 38 Sequel II or IIe instruments in the quarter, bringing the total installed base to 282 instruments, compared to 148 a year ago. 